This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hero, M. Articles by Dunkel, L. Search for Related Content PubMed PubMed Citation Articles by Hero, M. Articles by Dunkel, L. Related Collections Pediatric Endocrinology

Inhibition of Estrogen Biosynthesis with a Potent Aromatase Inhibitor Increases Predicted Adult Height in Boys with Idiopathic Short Stature: A Randomized Controlled Trial

Hospital for Children and Adolescents, University of Helsinki and Helsinki University Central Hospital (M.H.), Helsinki 00029 HUS, Finland; Goteborg Pediatric Growth Research Center, Institute for the Health of Women and Children, Goteborg University (E.N.), Goteborg S-41685, Sweden; and Department of Pediatrics, Kuopio University Hospital (L.D.), Kuopio 70211, Finland

Address all correspondence and requests for reprints to: Dr. Leo Dunkel, Department of Pediatrics, Kuopio University Hospital, P.O. Box 1777, 70211 Kuopio, Finland. E-mail: leo.dunkel{at}kuh.fi.

Context: In males as well as in females, estrogen is an essential regulator of bone maturation, growth plate fusion, and cessation of longitudinal growth. Therefore, an increase in predicted adult height (PAH) may be achieved in short boys by blocking estrogen biosynthesis.

Objective: We tested the hypothesis that a decrease in the rate of bone maturation and an increase in PAH can be achieved in boys with idiopathic short stature (ISS) by the method of blocking estrogen biosynthesis with an aromatase inhibitor. Secondarily, we investigated the effects of aromatase inhibition on bone mineralization.

Design: This was a prospective, double-blind, randomized, placebo (Pl)-controlled clinical study.

Setting: The study was performed at a university hospital out-patient clinic.

Patients: Thirty-one boys, aged 9.0–14.5 yr, with ISS were studied.

Intervention: The boys were treated with the aromatase inhibitor letrozole (Lz; 2.5 mg/d) or Pl for 2 yr.

Main Outcome Measure: The main outcome measure was the change in PAH after 24 months of treatment.

Results: PAH increased by 5.9 cm (P < 0.0001), and height SD score for bone age increased by 0.7 SD score (P < 0.0001) in the Lz-treated boys, whereas no changes occurred in the respective measures in Pl-treated boys. Areal bone mineral density of the lumbar spine and femoral neck, assessed by dual-energy x-ray absorptiometry, increased in a similar fashion in both groups during the treatment, whereas bone mineral apparent density increased only in those taking Lz (median increase, 4.3%; P = 0.009).

Conclusions: Treatment with the aromatase inhibitor Lz delays bone maturation and improves PAH in boys with ISS. No adverse effects on bone mineralization were evident after 2 yr of treatment.

This article has been cited by other articles:

				R. Nissel, A. Lindberg, O. Mehls, D. Haffner, and on behalf of the Pfizer International Growth Datab Factors Predicting the Near-Final Height in Growth Hormone-Treated Children and Adolescents with Chronic Kidney Disease J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1359 - 1365. [Abstract] [Full Text] [PDF]

				D. I. Shulman, G. L. Francis, M. R. Palmert, E. A. Eugster, and for the Lawson Wilkins Pediatric Endocrine Society Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development Pediatrics, April 1, 2008; 121(4): e975 - e983. [Abstract] [Full Text] [PDF]

				N. Mauras, L. Gonzalez de Pijem, H. Y. Hsiang, P. Desrosiers, R. Rapaport, I. D. Schwartz, K. O. Klein, R. J. Singh, A. Miyamoto, and K. Bishop Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 823 - 831. [Abstract] [Full Text] [PDF]

				A. M. Wikstrom, K. Bay, M. Hero, A.-M. Andersson, and L. Dunkel Serum Insulin-Like Factor 3 Levels during Puberty in Healthy Boys and Boys with Klinefelter Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4705 - 4708. [Abstract] [Full Text] [PDF]

				M. Hero, C. Ankarberg-Lindgren, M.-R. Taskinen, and L. Dunkel Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition Eur. J. Endocrinol., September 1, 2006; 155(3): 453 - 460. [Abstract] [Full Text] [PDF]

				D. B. Allen Growth Hormone Therapy for Short Stature: Is the Benefit Worth the Burden? Pediatrics, July 1, 2006; 118(1): 343 - 348. [Full Text] [PDF]